Learn from the best in healthcare. We present you with real-time developments and actionable strategies. Register to ask your immediate questions and to access our slides.
Avalere experts will host a lively discussion on the 2019 outlook for the medical device industry.
On January 10, Avalere experts examined the top healthcare priorities to watch in 2019.
Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.
Avalere experts discuss adult immunization rates in the United States and how the disparate coverage of vaccines under Medicare creates significant barriers to increasing adult immunization uptake.
Avalere experts are joined by Aledade CEO, Farzad Mostashari, MD, discussing the latest developments coming out of the Center for Medicare & Medicaid Innovation (CMMI).
Avalere experts discuss an evolving Medicaid program supported by a new administration and novel state approaches.
Avalere experts expand on significant priorities for 2018.
Avalere and Inovalon experts discuss the strategic advantages of leveraging our proprietary assets.
Learn more how analytics derived from proprietary commercial datasets empower provider executives to successfully partner across the healthcare industry.
Avalere experts discuss the need for unique stakeholder collaborations to facilitate success in the transition to a value-based care system.
Learn more about how new models of care are impacting providers as Avalere experts discuss care coordination and care transitions.
Avalere experts examine the challenges and successful approaches to outcomes-based contracts.
As the industry continues to see a shift from volume to value, Avalere experts examine the future of Medicare's Quality Payment Program under a new administration.
Avalere experts review proposed drug pricing policies from each stakeholder's perspective across the industry and the implications each might carry.
Avalere experts examine proposed key reforms to the ACA and its potential impacts.
Avalere experts discuss the top priorities to focus on as you navigate the new landscape.
With expanded administrative authority and flexibility to advance policy priorities through entities such as CMMI and IPAB, the new administration will shape the future of the Affordable Care Act, potential drug pricing reforms, and potential action on tax and/or entitlements.
Earler this month, the Obama Administration released the proposed Notice of Benefit and Payment Parameters (NBPP) for the 2018 plan year. Meanwhile, the exchange market faces instability. Recent Avalere analysis finds that more than one-third of rating regions may have only one insurance carrier participating on the exchange in 2017.
CMS released another mandatory bundled payment proposed rule which will significantly expand the scope of hospitals bearing risk for episodes of care nationally.
Recently we examined the various models of specialty pharmacy integration/ownership and how they result in different care coordination dynamics and access to drugs. Our findings demonstrate real value and opportunities in linking medical and pharmacy data to better support the patient journey with services and tools.